News

Company’s RenovoCath System Has Received Orphan Drug Designation from the FDA for its Innovative Approach. LOS ALTOS, Calif. – May 23, 2018 – RenovoRx, Inc., a medical technology company developing…

LOS ALTOS, CA – RenovoRx, a Silicon Valley-based medical device company, announced today that two teams of researchers treating patients with advanced non-metastatic pancreatic tumors reported beneficial effects including lengthened…

Aim: A dose escalation study of Gemcitabine for treatment of unresectable pancreatic cancer, using a targeted intra-arterial delivery catheter (RenovoCath™). Methods: 20 patients at two centers were enrolled with a…

LOS ALTOS, Calif., March 30, 2017 /PRNewswire/ — RenovoRx, manufacturer of the RenovoCath adjustable dualballoon infusion catheter, today, announced it has received FDA 510(k) clearance to expand its indications for…

Dr. David Madoff of NewYork-Presbyterian Hospital Weill Cornell Medical Center presented on his experience using novel technologies and techniques in difficult to treat tumor cases at the AIM/VEITH Symposium, November…

RenovoCath™ Catheter Awarded Two Device Patents LOS ALTOS, Calif., Oct. 13, 2016 — RenovoRx, a leading developer of innovative solutions for targeted therapy today announced that the company has received…

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the peripheral vascular system, today announced that the company achieved the CE Mark for…